IDEXX Laboratories, Inc. (IDXX) Shares Sold by Aperio Group LLC

Aperio Group LLC lessened its stake in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 2.8% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 43,125 shares of the company’s stock after selling 1,264 shares during the period. Aperio Group LLC’s holdings in IDEXX Laboratories were worth $6,744,000 at the end of the most recent reporting period.

Several other large investors also recently modified their holdings of the stock. Victory Capital Management Inc. increased its stake in shares of IDEXX Laboratories by 10.2% in the fourth quarter. Victory Capital Management Inc. now owns 11,500 shares of the company’s stock worth $1,798,000 after buying an additional 1,060 shares during the last quarter. Front Row Advisors LLC bought a new stake in IDEXX Laboratories during the fourth quarter valued at $649,000. Kornitzer Capital Management Inc. KS bought a new stake in IDEXX Laboratories during the fourth quarter valued at $3,096,000. Investment House LLC bought a new stake in IDEXX Laboratories during the fourth quarter valued at $289,000. Finally, Zurcher Kantonalbank Zurich Cantonalbank increased its stake in IDEXX Laboratories by 8.9% during the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 21,876 shares of the company’s stock valued at $3,421,000 after purchasing an additional 1,787 shares during the last quarter. Institutional investors and hedge funds own 86.50% of the company’s stock.

Several analysts have weighed in on the stock. Canaccord Genuity reiterated a “buy” rating and set a $210.00 target price on shares of IDEXX Laboratories in a research note on Monday, January 29th. BidaskClub upgraded shares of IDEXX Laboratories from a “hold” rating to a “buy” rating in a research note on Tuesday, January 16th. Piper Jaffray Companies boosted their target price on shares of IDEXX Laboratories to $211.00 and gave the company an “overweight” rating in a research note on Thursday, February 1st. Zacks Investment Research upgraded shares of IDEXX Laboratories from a “hold” rating to a “strong-buy” rating and set a $214.00 target price for the company in a research note on Monday, February 5th. Finally, Stifel Nicolaus reiterated a “buy” rating and set a $185.00 target price on shares of IDEXX Laboratories in a research note on Tuesday, October 24th. One research analyst has rated the stock with a sell rating, six have given a buy rating and one has given a strong buy rating to the stock. IDEXX Laboratories has a consensus rating of “Buy” and an average price target of $194.00.

IDEXX Laboratories, Inc. (IDXX) opened at $175.06 on Tuesday. The company has a market cap of $15,340.00, a PE ratio of 59.54, a PEG ratio of 2.13 and a beta of 0.58. The company has a current ratio of 0.97, a quick ratio of 0.80 and a debt-to-equity ratio of -11.26. IDEXX Laboratories, Inc. has a 12-month low of $140.63 and a 12-month high of $198.73.

IDEXX Laboratories (NASDAQ:IDXX) last released its quarterly earnings results on Thursday, February 1st. The company reported $0.77 EPS for the quarter, topping the consensus estimate of $0.73 by $0.04. The business had revenue of $506.00 million during the quarter, compared to analyst estimates of $490.51 million. IDEXX Laboratories had a net margin of 13.36% and a negative return on equity of 432.19%. The company’s quarterly revenue was up 14.2% on a year-over-year basis. During the same quarter in the prior year, the firm earned $0.58 earnings per share. research analysts expect that IDEXX Laboratories, Inc. will post 4.09 EPS for the current fiscal year.

In other news, Chairman Jonathan W. Ayers sold 22,000 shares of the company’s stock in a transaction dated Thursday, February 8th. The shares were sold at an average price of $177.52, for a total transaction of $3,905,440.00. Following the completion of the transaction, the chairman now owns 1,077,112 shares in the company, valued at $191,208,922.24. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Jonathan W. Ayers sold 18,000 shares of the company’s stock in a transaction dated Thursday, November 16th. The stock was sold at an average price of $153.61, for a total transaction of $2,764,980.00. Following the transaction, the chief executive officer now owns 1,064,573 shares of the company’s stock, valued at approximately $163,529,058.53. The disclosure for this sale can be found here. Insiders have sold 104,762 shares of company stock valued at $17,967,464 in the last 90 days. Insiders own 2.77% of the company’s stock.

WARNING: This report was originally posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this report on another domain, it was illegally copied and republished in violation of United States & international trademark and copyright law. The original version of this report can be viewed at https://www.dispatchtribunal.com/2018/02/13/idexx-laboratories-inc-idxx-shares-sold-by-aperio-group-llc.html.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc develops, manufactures and distributes products and provides services for the companion animal veterinary, livestock and poultry, dairy and water testing markets. The Company also sells a line of portable electrolytes and blood gas analyzers for the human point-of-care medical diagnostics market.

Want to see what other hedge funds are holding IDXX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for IDEXX Laboratories, Inc. (NASDAQ:IDXX).

Institutional Ownership by Quarter for IDEXX Laboratories (NASDAQ:IDXX)

Receive News & Ratings for IDEXX Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IDEXX Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply